Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2023.04.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-label dermatologic uses of IL-23 inhibitors.
J Dermatolog Treat
December 2024
Department of Dermatology, University of Illinois College of Medicine, Chicago, IL, USA.
Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.
Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.
Guselkumab - In Psoriasis and Beyond.
Dermatol Pract Concept
July 2024
Department of Dermatology, Katihar Medical College, Karim Bagh, Katihar, Bihar, India.
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration for the management of moderate to severe psoriasis. Apart from its utility in psoriasis, there are a number of other dermatologic conditions where guselkumab has demonstrated value.
Objectives: The aim of this narrative review is to describe the utility of guselkumab in psoriasis as well as its implication in off-label dermatologic disorders.
Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris.
Arch Dermatol Res
June 2024
Dermatology Partners, Macungie, PA, USA.
Article Synopsis
- Pityriasis rubra pilaris (PRP) is a rare skin condition featuring salmon-colored plaques and hard skin on palms and soles, with traditional treatments often ineffective and risky.
- Recent interest has shifted towards the off-label use of IL-23 inhibitors, specifically risankizumab and guselkumab, which are approved for psoriasis and show promise in treating PRP.
- A review of 10 studies revealed that risankizumab improved symptoms in 10 out of 11 patients, while guselkumab led to complete clearance in 3 out of 5, but results varied, indicating the need for larger studies to confirm effectiveness and safety.
Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
Clin Drug Investig
July 2023
Department of Hospital Pharmacy, La Paz University Hospital, Autonomous University of Madrid, Madrid, Spain.
Background: Guselkumab is a drug used to treat moderate to severe plaque psoriasis. However, real-life clinical data on its off-label use are limited, especially regarding the optimal drug dosage regimen for different patient profiles.
Objective: The main objective of this real-world, single-centre, retrospective study was to identify the off-label guselkumab dosing regimen used in clinical practice.
Off-label use of guselkumab for pyoderma gangrenosum.
Med Clin (Barc)
September 2023
Servicio de Farmacia, Hospital Público de la Mariña, Lugo, España.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!